Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
Titel:
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
Auteur:
Earl, H.M. Hiller, L. Dunn, J.A. Blenkinsop, C. Grybowicz, L. Vallier, A.-L. Gounaris, I. Abraham, J.E. Hughes-Davies, L. McAdam, K. Chan, S. Ahmad, R. Hickish, T. Rea, D. Caldas, C. Bartlett, J.M.S. Cameron, D.A. Provenzano, E. Thomas, J. Hayward, R.L.